All stock lists
Ormat Technologies, Inc. (New York Stock Exchange:ORA)
US · Delayed Price · Currency is USD
Also listed: 0KDH.L, HNM.DE, HNM.F, ORA.TAUtilities · Renewable Utilities
94.34+0.15 (+0.16%)
Market cap
$5.80B
Insider Score
Health Score
Analyst consensus
Listed since
Nov 11, 2004
Website
Insider Score
––Not scored
ORA Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
ORA analyst forecast
ORA analyst consensus
Moderate Buy6 ratings
Buy 3 Hold 3 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ORA 12-month price target
$131.00+39.0% upsideaverage of 2 firms
$145.00High
$117.00Low
ORA ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ORA
- Barclays100%success rate · +43.5% avg return · 3 calls
- Piper Sandler100%success rate · +5.7% avg return · 1 call
- Baird100%success rate · +8.6% avg return · 1 call
- UBS67%success rate · -4.3% avg return · 3 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ORA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-10-19 |
| — | UBS | Neutral | — | — | Downgraded | 2026-10-01 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-09-09 |
| Oppenheimer | Outperform | $145.00 | +34.3% | Reiterated | 2026-09-09 | |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-09-09 |
| Jefferies | — | $117.00 | +8.4% | — | 2026-09-09 | |
| — | Bernstein | Market Perform | — | — | Upgraded | 2026-09-04 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-10 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-08-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-16 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-05-18 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-05-08 |
| — | UBS | Buy | — | — | Reiterated | 2026-05-08 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-08 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-04-16 |
| — | UBS | Buy | — | — | Reiterated | 2026-03-03 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-03-02 |
| — | Baird | Outperform | — | — | Reiterated | 2026-02-27 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-02-18 |
| — | Jefferies | Hold | — | — | Downgraded | 2026-02-13 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-01-27 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-01-15 |
| — | TD Cowen | Buy | — | — | Upgraded | 2026-01-09 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-12-18 |
| — | UBS | Buy | — | — | Reiterated | 2025-11-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-11-07 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-11-05 |
| — | TD Cowen | Hold | — | — | Reiterated | 2025-11-05 |
| — | Roth Capital | Buy | — | — | Reiterated | 2025-11-05 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-10-16 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-10-07 |
| — | Piper Sandler | Overweight | — | — | Upgraded | 2025-09-17 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2025-08-19 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-08-08 |
| — | Roth Capital | Buy | — | — | Reiterated | 2025-08-05 |
| — | Baird | Outperform | — | — | Upgraded | 2025-07-30 |
| — | UBS | Buy | — | — | Reiterated | 2025-07-24 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-07-22 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-07-10 |
| — | Barclays | Overweight | — | — | Upgraded | 2025-06-06 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-05-08 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-03-25 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-02-28 |
| — | Jefferies | Buy | — | — | Upgraded | 2025-02-20 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-11-08 |
| — | Roth MKM | Buy | — | — | Reiterated | 2024-11-08 |
| — | Roth MKM | Buy | — | — | Reiterated | 2024-08-12 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-08-08 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2024-07-16 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-06-21 |
| — | UBS | Buy | — | — | Reiterated | 2024-05-14 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2024-05-13 |
| — | TD Cowen | Hold | — | — | Reiterated | 2024-05-10 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2024-02-05 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-01-19 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2023-10-19 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-10-12 |
| — | Roth MKM | Buy | — | — | Upgraded | 2023-08-07 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-06-27 |
| — | Citigroup | Neutral | — | — | Reiterated | 2023-06-16 |
ORA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-25 | 0.67 | 0.67 | $257.7M | $276.0M |
| 2026-05-06 | 0.92 | 1.30 | $349.2M | $403.9M |
| 2026-08-05 | 0.26 | 0.50 | $240.0M | $258.8M |
| 2026-11-04 | 0.33 | 0.56 | $248.4M | $275.1M |
| 2027-02-24Upcoming | 0.54 | — | $269.6M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.